Effectiveness of Belumosudil for the Treatment of Chronic GVHD
Research type
Research Study
Full title
Real-World Effectiveness of Belumosudil for the Treatment of Chronic Graft vs. Host Disease: A Non-interventional Retrospective Cohort Study Using Patient Medical Records
IRAS ID
357906
Contact name
Varun Mehra
Contact email
Sponsor organisation
Sanofi
Duration of Study in the UK
0 years, 6 months, 3 days
Research summary
This will be a retrospective non-interventional multi-center multi-country cohort study. Patients with cGVHD initiating belumosudil in line with local label (UK) or as part of compassionate use programs (Spain and Italy) will be retrospectively identified via medical chart reviews based on the eligibility criteria. Given the retrospective observational nature of study design, the study will not have any impact on routine management of cGVHD. Patients will only be included in the study if they previously initiated belumosudil (at physician’s discretion) before the date of site initiation (date of contract execution with the site), whichever is the latest. The review of charts will be performed at a single point in time.
REC name
Wales REC 4
REC reference
25/WA/0213
Date of REC Opinion
16 Jul 2025
REC opinion
Favourable Opinion